<DOC>
	<DOCNO>NCT00642655</DOCNO>
	<brief_summary>The purpose study examine safety efficacy IVIG combination Rituximab low level HLA-sensitive antibody block ability attack transplant organ patient highly HLA-sensitized await transplantation .</brief_summary>
	<brief_title>Rituximab Intravenous Immunoglobulin ( IVIG ) Desensitization Renal Transplantation</brief_title>
	<detailed_description>Patients eligible study anti-HLA antibody ( Panel Reactive Antibody { PRA } ) &gt; 30 % . If patient meet criterion , patient ask assessment ability IVIG reduce anti-HLA antibody activity test tube . Patients receive IVIG 2gm/kg x1 hemodialysis . Seven day later , patient receive Rituximab 1gm CSMC Infusion Center per protocol Rituximab infusion . The second Rituximab infusion day # 22 . Additional IVIG infusion give month one . Patients continue follow additional 12 month last IVIG infusion ask return follow visit month 1 5 , month 7 12 .</detailed_description>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<criteria>Patients eligible study antiHLA antibody ( Panel Reactive Antibody [ PRA ] ) &gt; 30 % eligible transplantation CedarsSinai Medical Center . We currently anticipate enter 20 patient course study . We currently ~100 patient wait list would meet criterion . Patients select base ability IVIG inhibit cytotoxic antiHLA antibody activity vitro . They receive IVIG 2gm/kg X1 day 1 hemodialysis . Seven day later , patient receive Rituxan® 1gm CSMC Cancer Infusion Center per protocol Rituxan® infusion . The second Rituxan® infusion day # 22 . The patient monitor antiHLA antibody outline test show . Able willing give write informed consent comply requirement study protocol Adequate liver function , indicate normal liver function test ( NL : AST , ALT , Bilirubin negative test hepatitis C hepatitis B . Negative serum pregnancy test ( woman child bear age ) Men woman reproductive potential must agree use acceptable method birth control treatment twelve month ( 1 year ) completion treatment . Treatment investigational agent within 4 week screen 5 halflives investigational drug ( whichever longer ) Receipt live vaccine within 4 week prior randomization Previous Treatment Rituximab ( MabThera® / Rituxan® ) Prior antibody therapy History severe allergic anaphylactic reaction humanize murine monoclonal antibody History HIV ( positive HIV , HIV conduct screen ) History Hepatitis B and/or Hepatitis C History recurrent significant infection history recurrent bacterial infection Known active bacterial , viral fungal mycobacterial , infection ( include tuberculosis atypical mycobacterial disease , exclude fungal infection nail bed ) major episode infection require hospitalization treatment i.v . antibiotic within 4 week screen oral antibiotic within 2 week prior screen Lack peripheral venous access History drug , alcohol , chemical abuse within 6 month prior screen Pregnancy ( negative serum pregnancy test perform woman childbearing potential within 7 day treatment ) lactation Concomitant malignancies previous malignancy within last five year , exception adequately treat basal squamous cell carcinoma skin carcinoma situ cervix . History psychiatric disorder Significant cardiac pulmonary disease ( include obstructive pulmonary disease ) Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render patient high risk treatment complication Inability comply study followup procedure Laboratory Exclusion Criteria ( Screening ) Hemoglobin : &lt; 8.5 gm/dL Platelets : &lt; 100,000/mm AST ALT &gt; 2.5 x Upper Limit Normal unless related primary disease . Positive Hepatitis B C serology Positive HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>IVIG</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Highly Sensitized</keyword>
	<keyword>Kidney Transplantation</keyword>
</DOC>